Kensey Nash Corp.
Division of Royal DSM NV
Latest From Kensey Nash Corp.
Researchers have been working for years to develop a reliable and cost-effective means of regenerating the hyaline cartilage found in the knee, with the aim of offering a minimally invasive treatment option for the millions of patients with painful knee osteoarthritis. Although this goal has been elusive so far, recent progress suggests the field may have turned a corner, and a large number of companies are now competing to win this quest, which many refer to as the “Holy Grail” of knee OA.
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
A roundup of recent medtech mergers & acquisitions, strategic alliances, and financings.
Deal worth $360 million will help establish DSM as a major device industry materials supplier, strengthening offerings of bio-passive, bio-active and bio-interactive materials technologies.
- Implantable Devices
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- Wound Healing & Tissue Repair
- North America
- Parent & Subsidiaries
- Royal DSM NV
- Senior Management
Joseph W Kaufmann, Pres. & CEO
Michael Celano, CFO
William A Fiehler, VP, Product Dev.
- Contact Info
Kensey Nash Corp.
Phone: (484) 713-2100
735 Pennsylvania Dr.
Exton, PA 19341
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.